Biosortia works on new drugs from deep access to the chemistry of the microbiome for immuno-oncology and immunological therapeutics.
Biosortia Microbiomics has unique access to the hidden chemistry of the microbiome. The only capability in the world to obtain the long-sought, but previously unobtainable drug-like molecules directly from the microbiome leading to direct access of hidden molecules and filling the key missing data for artificial intelligence (AI).
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 1, 2016 | Seed | $8M | 1 |
Keiretsu Forum
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Keiretsu Forum
|
Yes | Seed |